Compound Evidence File
#EC-2026-0492
NandroMix 300
Filed under Injectable Oils. The bureau holds 127 laboratory returns for this compound from 58 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
58 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 10.0 | 10.0 | 21 May 2026 | 21 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 10.0 | 10.0 | 13 Feb 2026 | 1 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Apr 2026 | 2 Aug 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Jun 2026 | 7 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Feb 2026 | 4 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 22 Jul 2026 | 12 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 24 Jan 2026 | 13 Feb 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 10.0 | 10.0 | 10.0 | 10 Feb 2026 | 24 Apr 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Mar 2026 | 13 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 9.9 | 9.9 | 10.0 | 19 Nov 2025 | 19 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 4 Apr 2026 | 16 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Mar 2026 | 16 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Mar 2026 | 10 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 27 Dec 2025 | 2 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 9.9 | 7 May 2026 | 20 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 24 Apr 2026 | 2 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 9.9 | 12 Apr 2026 | 25 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Mar 2026 | 11 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 26 Feb 2026 | 15 Apr 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 1 Feb 2026 | 17 Apr 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Apr 2026 | 8 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Feb 2026 | 16 Feb 2026 |
| Xianhong Tong XHT PeptidesCASE #VI-2026-0997 | X | 1 | 9.8 | 9.8 | 9.8 | 7 May 2025 | 7 May 2025 |
| Dankang BioHealthCASE #VI-2026-0775 | X | 1 | 9.6 | 9.6 | 9.6 | 11 Jun 2025 | 11 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.6 | 6.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.5 | 7.2 | 10.0 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.3 | 7.3 | 10.0 | 23 May 2026 | 23 May 2026 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 8.2 | 8.2 | 8.2 | 17 Dec 2024 | 17 Dec 2024 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.1 | 6.7 | 9.3 | 24 May 2026 | 24 May 2026 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 8.1 | 8.1 | 8.1 | 21 May 2025 | 21 May 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 8.1 | 8.1 | 8.1 | 8 Jul 2025 | 8 Jul 2025 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 7.8 | 7.8 | 7.8 | 16 Mar 2025 | 16 Mar 2025 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 3 | 7.7 | 6.4 | 8.6 | 27 Feb 2025 | 24 May 2026 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 7.6 | 7.6 | 7.6 | 13 Feb 2025 | 13 Feb 2025 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 7.6 | 7.6 | 7.6 | 8 Jul 2025 | 8 Jul 2025 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 7.5 | 7.5 | 7.5 | 20 Jun 2025 | 20 Jun 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 7.3 | 6.5 | 8.0 | 24 May 2026 | 24 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 3 | 7.2 | 6.0 | 8.9 | 20 Jun 2025 | 21 May 2026 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 7.1 | 7.1 | 7.1 | 25 Apr 2025 | 25 Apr 2025 |
| Xingruida XDRCASE #VI-2026-0898 | X | 4 | 6.7 | 6.2 | 7.5 | 11 Jun 2025 | 26 Jan 2026 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 2 | 6.7 | 6.1 | 7.3 | 3 Jul 2025 | 26 Jan 2026 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 6.7 | 6.7 | 6.7 | 3 Jun 2025 | 3 Jun 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 3 | 6.4 | 4.8 | 7.7 | 25 Apr 2025 | 20 May 2026 |
| ScienceCASE #VI-2026-0636 | X | 1 | 5.7 | 5.7 | 5.7 | 9 Jun 2025 | 9 Jun 2025 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 5.3 | 5.3 | 5.3 | 3 Jul 2025 | 3 Jul 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 5.0 | 5.0 | 5.0 | 8 Jul 2025 | 8 Jul 2025 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 4.7 | 4.7 | 4.7 | 2 Apr 2025 | 2 Apr 2025 |
| Allen Biotechnology Co ABCCASE #VI-2026-0709 | X | 1 | 4.7 | 4.7 | 4.7 | 7 May 2025 | 7 May 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 4.2 | 4.2 | 4.2 | 20 Jun 2025 | 20 Jun 2025 |
| Peptides For SaleCASE #VI-2026-0614 | X | 1 | 4.1 | 4.1 | 4.1 | 6 May 2025 | 6 May 2025 |
| Swiss ChemsCASE #VI-2026-0030 | X | 1 | 3.8 | 3.8 | 3.8 | 7 May 2025 | 7 May 2025 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 3.6 | 3.6 | 3.6 | 24 Apr 2025 | 24 Apr 2025 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 3.3 | 3.3 | 3.3 | 13 Feb 2025 | 13 Feb 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 2.6 | 2.6 | 2.6 | 3 Jun 2025 | 3 Jun 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 0.5 | 0.5 | 0.5 | 8 Jul 2025 | 8 Jul 2025 |
| Guangzhou Yuao TradingCASE #VI-2026-0787 | X | 1 | 0.0 | 0.0 | 0.0 | 17 Dec 2024 | 17 Dec 2024 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.0 | 0.0 | 0.0 | 8 Jul 2025 | 8 Jul 2025 |
Open any subject to view the batch-level evidence for NandroMix 300 alone.